title: Effect of creatine and pioglitazone on Hk-2 cell line cisplatin nephrotoxicity.
abstract: Cisplatin is a chemotherapeutic agent, which is used in the treatment of various solid organ cancers, and its main dose limiting side effect of cisplatin is nephrotoxicity. The aim of this study is to investigate the role of pioglitazone and creatine on cisplatin nephrotoxicity in vitro. Real-time cell analyzer system (RTCA) was used for real-time and time-dependent analysis of the cellular response of HK-2 cells following incubation with cisplatin and combination with creatine or pioglitazone hydrochloride. First, half-maximal inhibitory concentrations (IC50) of cisplatin, creatine and pioglitazone were calculated by RTCA system. Afterwards creatine and pioglitazone was administered with serial dilutions under RTCA system. IC50 dose for cisplatin was 7.69 M × 10(-5) at 24th hour and 3.93 M × 10(-6) at 48th hour. IC50 dose for pioglitazone was 1.61 M × 10(-3) at 24th hour and 2.85 M × 10(-4) at 48th hour. Although cells were treated the dose of 40,225 mM creatine, IC50 dose could not been reached. Neither pioglitazone nor creatine had additional protective effect in any dose. Consequently, beneficial effect of creatine and pioglitazone on cisplatin-induced cell death could not be found. Further studies and clinical trials are needed to evaluate the effect of different doses of these drugs in cisplatin-induced nephrotoxicity.
authors.affiliation: Pediatric Nephrology Department, Ondokuz Mayis University Faculty of Medicine, Children's Hospital , Samsun , Turkey and.
authors.forename: Gurkan
authors.initials: G
authors.lastname: Genc
authors.forename: Veli
authors.initials: V
authors.lastname: Kilinc
authors.forename: Abdulkerim
authors.initials: A
authors.lastname: Bedir
authors.forename: Ozan
authors.initials: O
authors.lastname: Ozkaya
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002460:Cell Line; D002945:Cisplatin / Q000009:adverse effects*; D003401:Creatine / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000077205:Pioglitazone; D051437:Renal Insufficiency / Q000139:chemically induced / Q000517:prevention & control*; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D003401:Creatine; D002945:Cisplatin; D000077205:Pioglitazone
keywords: Drug toxicity; cisplatin; creatine; pioglitazone